The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
GI Malignancies Debate 2022 | Treatment options for appendix cancer
Deepa Magge, MD, FACS, Vanderbilt-Ingram Cancer Center, Nashville, TN, comments on the management of appendix cancer, an uncommon cancer with an increasing rate of incidence. A majority of patients will have mucinous tumors and an appendectomy is often provided in patients with low grade tumors. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) are offered for patients with differentiated tumors, whereas a right hemicolectomy is recommended for patients with moderately or poorly differentiated tumors. This interview took place virtually at the 2022 Great Debates & Updates in Gastrointestinal Malignancies Congress.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
